NEWS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Immune Design Announces Positive FDA Feedback on Phase 3 Clinical Trial Design for CMB305 in Synovial Sarcoma Patients
CMB305 Monotherapy vs. Placebo in the Maintenance Setting PFS Analysis for Potential Full Approval as Early as 24 Months After Study Start Conference Call and Webcast Tomorrow at 5:30am PT/8:30am ET SEATTLE and SOUTH SAN FRANCISCO, Calif., Oct. 16, 2017 (GLOBE NEWSWIRE) -- Immune Design
View HTML
Toggle Summary Immune Design Announces Four Upcoming Presentations at the SITC 32nd Annual Meeting
SEATTLE and SOUTH SAN FRANCISCO, Calif., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that four abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 32 nd Annual
View HTML
Toggle Summary New Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit and Immune Response
Phase 2 Interim Analysis Data Presented at ESMO 2017 Congress SEATTLE and SOUTH SAN FRANCISCO, Calif., Sept. 08, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that an interim analysis of its ongoing, randomized
View HTML
Toggle Summary Immune Design to Present at Upcoming Investor Conferences in September
SEATTLE and SOUTH SAN FRANCISCO, Calif., Sept. 01, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that the company will present at two upcoming investor conferences in September.
View HTML
Toggle Summary Immune Design Announces New CMB305 + Checkpoint Inhibitor Topline Data from an Upcoming Presentation at the ESMO 2017 Congress
Interim data analysis shows greater clinical benefit and immune response with CMB305+atezolizumab than with atezolizumab alone SEATTLE and SOUTH SAN FRANCISCO, Calif., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today
View HTML
Toggle Summary Immune Design Reports Second Quarter 2017 Financial Results and Provides Corporate Update
Company conference call at 1:30 p.m. PT today
View HTML
Toggle Summary Immune Design to Report Second Quarter 2017 Financial Results & Provide Corporate Update
SEATTLE and SOUTH SAN FRANCISCO, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will report second quarter 2017 financial results and provide a corporate update after the close of U.S.
View HTML
Toggle Summary Immune Design Updates Positive Data from Lead Cancer Immunotherapy Programs at ASCO Annual Meeting
Observed median overall survival for sarcoma patients treated in two separate Phase 1 studies with an NY-ESO-1 targeted novel immunotherapy meaningfully exceeds standard of care benchmarks In follicular NHL patients, intratumoral immunization with G100 induced objective responses ( ≥ 50%
View HTML
Toggle Summary Immune Design to Present at Jefferies 2017 Global Healthcare Conference
SEATTLE and SOUTH SAN FRANCISCO, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that Carlos Paya, M.D., Ph.D., President and Chief Executive Officer, will present at the Jefferies 2017 Global
View HTML
Toggle Summary New Clinical and Biomarker Data Validate Immune Design's Lead Programs and Discovery Platforms
Data from CMB305 and G100 to be Presented at ASCO Annual Meeting in June 2017 SEATTLE and SOUTH SAN FRANCISCO, May 17, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, reported new clinical and biomarker data today from CMB305 and
View HTML